Abstracts

745 – HIV Drug Resistance by Next-Generation Sequencing After Transition to TLD in Uganda and South Africa

Background Studies have identified an increased risk of dolutegravir (DTG) resistance in people with nucleos(t)ide (NRTI) resistance after transitioning from non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) to tenofovir/lamivudine/dolutegravir (TLD). However, the frequency of this occurrence in programmatic settings, as well as the impact of NRTI resistance on emergence of DTG resistance minority variants,…

702 – A Multicenter Study of Albuvirtide Combined With 3BNC117 in Multidrug-Resistant HIV-1 Infection

Background For some individuals with HIV-1 infection who have failed multiple antiretroviral regimens and have limited treatment options, there is an urgent need for new antiretroviral drugs with novel mechanisms of action. Albuvirtide (ABT) is an HIV-1 fusion inhibitor and 3BNC117 is an HIV-specific, broadly neutralizing monoclonal antibody. We aimed to assess the efficacy and safety…

704 – Evaluating Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube

Background Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen (STR) with no recommendations from the manufacturer regarding crushing or dissolving tablets for adult use. However, oral ingestion may be impractical for hospitalized individuals requiring enteral feeding. Despite some healthcare institutions administering B/F/TAF in crushed or dissolved form in such cases, there is limited clinical evidence regarding the efficacy…

744 – Plasma Dolutegravir Exposure as a Triaging Tool for HIV Drug Resistance Testing by ONT Sequencing

Background South African antiretroviral therapy (ART) guidelines recommend dolutegravir (DTG) based regimens. Although DTG resistance is infrequently reported, it is paramount to identify individuals at risk for resistance. We assessed the use of plasma DTG (pDTG) drug-exposure (DE) testing as a triaging tool to identify individuals at highest risk for DTG resistance. Additionally, we assessed…

742 – Population-Based Longitudinal Dynamics of HIV Drug Resistance During Dolutegravir Rollout in Uganda

Background African countries have shifted to dolutegravir (DTG)-based first-line HIV treatment. However, population-based studies of resistance trends through DTG roll-out in sub-Saharan Africa are extremely limited. Methods We analyzed data from the Rakai Community Cohort Study, an open population-based cohort, during five survey rounds between 2012 and 2022. Consenting people aged 15-49 years were interviewed…

721 – The Genetic Barrier to Resistance to LEN Is Not Affected by Non-B Subtypes or Treatment Exposure

Background Lenacapavir (LEN) is a HIV-1 capsid inhibitor approved for heavily-treatment experienced (HTE) people with HIV (PWH). This in vitro study aimed to evaluate LEN susceptibility and genetic barrier in B and non-B subtypes derived from therapy naïve (TN) and HTE PWH. Methods Thirty-one NL4-3 based recombinant viruses harbouring clinically derived GAG-PR region were generated…

732 – Despite Increasing Use of INIs to Treat HIV Infection, Resistance to This Class Remains Stable

Background Since the beginning of HIV treatment, changes in the use of antiretroviral (ARV) drugs have often led to changes in HIV resistance mutation patterns. The integrase inhibitor (INI) class has benefited from many developments: first raltegravir (RAL) and elvitegravir (EVG), followed by dolutegravir (DTG), cabotegravir (CAB) and bictegravir (BIC). The aim of this study…

680 – Impact of Oral Lead-In on PK and Virologic Outcomes in People With HIV Transitioning to CAB+RPV LA

Background For people with HIV (PWH) on antiretroviral therapy (ART), transitioning to bimonthly long-acting (LA) injectable cabotegravir (CAB) plus rilpivirine (RPV) can be done either directly (non-OLI) or after an optional one-month oral lead-in (OLI). Recent data suggest lower CAB trough concentrations (Ctrough) with non-OLI initiation. This study aimed to assess pharmacokinetics (PK) and virological…

739 – Real-World Robustness of B/F/TAF at Virologic Failure in the ANRS-CO3-AquiVIH-NA Cohort

Background Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a high potent and simplified antiretroviral therapy (ART) regimen as shown by clinical trials. However, real-world evidence in individuals experiencing a virologic failure (VF) remains limited. We investigated the virological outcomes in participants who experienced VF after switching to B/F/TAF. Methods We conducted a retrospective study using data from the…

738 – Bictegravir + Lenacapavir: Baseline and Week 48 Resistance in ARTISTRY-1 Phase II

Background ARTISTRY-1 is a Phase 2/3 study evaluating the safety and efficacy of the complete regimen of the capsid inhibitor lenacapavir (LEN) given with the integrase strand-transfer inhibitor (INSTI) bictegravir (BIC) compared to remaining on a complex multi-tablet regimen. Virologically suppressed participants with no known INSTI resistance mutations were enrolled in the Phase 2 portion. At…